Cargando…

Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells

c-Jun is a major constituent of AP-1 transcription factor that transduces multiple mitogen growth signals, and it is frequently overexpressed in non-small cell lung cancers (NSCLCs). Earlier, we showed that blocking AP-1 by the overexpression of a c-Jun dominant-negative mutant, TAM67, inhibited NSC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kikuchi, J, Kinoshita, I, Shimizu, Y, Oizumi, S, Nishimura, M, Birrer, M J, Dosaka-Akita, H
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607224/ https://www.ncbi.nlm.nih.gov/pubmed/19018257 http://dx.doi.org/10.1038/sj.bjc.6604782

Ejemplares similares

Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant
por: Shimizu, Y, et al.
Publicado: (2008)

γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer
por: Mizugaki, H, et al.
Publicado: (2012)

Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines
por: Mohammed, M Z, et al.
Publicado: (2011)

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non‐small‐cell lung cancer cells
por: Takashina, Taichi, et al.
Publicado: (2016)

Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2α overexpression
por: Jonckheere, N, et al.
Publicado: (2009)

Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade
por: Loebinger, M R, et al.
Publicado: (2008)

Expression of Bim, Noxa, and Puma in non-small cell lung cancer
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2012)

Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
por: Mahalingam, D, et al.
Publicado: (2011)

Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours
por: Green, J, et al.
Publicado: (2006)

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways
por: Zhang, Hao, et al.
Publicado: (2016)

Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells
por: Carbajo-Pescador, S, et al.
Publicado: (2013)

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
por: Lin, Y, et al.
Publicado: (2012)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma
por: Yu, H, et al.
Publicado: (2015)

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
por: Konecny, G E, et al.
Publicado: (2008)

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma
por: Bilim, V, et al.
Publicado: (2009)

Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells
por: Tao, Y, et al.
Publicado: (2007)

LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2017)

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017)

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer
por: Granata, A, et al.
Publicado: (2014)

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib
por: Courtin, Aurelie, et al.
Publicado: (2016)

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation
por: Loriot, Y, et al.
Publicado: (2010)

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
por: Johnson, N, et al.
Publicado: (2010)

Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours
por: Beloueche-Babari, M, et al.
Publicado: (2015)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
por: Morgillo, F, et al.
Publicado: (2011)

Inhibitory effect of a TGFβ receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells
por: Shinto, O, et al.
Publicado: (2010)

Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
por: He, G, et al.
Publicado: (2013)

Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile
por: Giovannetti, E, et al.
Publicado: (2005)

Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007)

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
por: Fischel, J-L, et al.
Publicado: (2005)

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013)

Attenuation of muscle atrophy in a murine model of cachexia by inhibition of the dsRNA-dependent protein kinase
por: Eley, H L, et al.
Publicado: (2007)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer
por: Nomura, S, et al.
Publicado: (2008)

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
por: Tekle, C, et al.
Publicado: (2008)

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells
por: Troiani, T, et al.
Publicado: (2012)

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
por: Agarwal, S, et al.
Publicado: (2009)

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase
por: Kelly, M P, et al.
Publicado: (2012)

Treatment decisions and survival for people with small-cell lung cancer
por: Powell, H A, et al.
Publicado: (2014)

Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance
por: Kaliszczak, M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2lta304uc3tdsncg4r30fo4vhu